



TOMÁS J. ARAGÓN, M.D., Dr.P.H
State Public Health Officer & Director

State of California—Health and Human Services Agency
California Department of Public Health



GAVIN NEWSOM
Governor

Office of AIDS (OA)
PrEP Assistance Program (PrEP-AP)

Provider Policy Memorandum
Memorandum Number: 2021-01

DATE: January 5, 2021

TO: PREP-AP CLINICAL NETWORK PROVIDERS

SUBJECT: **PrEP-AP GENERIC PrEP POLICY**

Overview

The purpose of this memo is to inform contracted clinical providers in the Pre-Exposure Prophylaxis (PrEP) Assistance Program (PrEP-AP) Network of policy requirements enforced by the PrEP-AP with respect to Generic PrEP.

Background

A generic version of the human immunodeficiency virus (HIV) PrEP combination medication tenofovir disoproxil fumarate/emtricitabine became available on October 2, 2020. Generic tenofovir disoproxil fumarate/emtricitabine was added to the PrEP-AP Formulary January 4, 2021. The PrEP-AP Generic PrEP Policy outlines changes to PrEP-AP due to the introduction of the first generic version of an HIV PrEP medication and explains the changes to covered medications by PrEP-AP client type. The PrEP-AP Generic PrEP Policy Flowchart provides a graphic representation of the information detailed in the PrEP-AP Generic PrEP Policy.

The generic version of tenofovir disoproxil fumarate/emtricitabine is manufactured by Teva Pharmaceuticals, which has also established an Emtricitabine and Tenofovir Disoproxil Fumarate Tablets Savings Card to be used towards the cost of the copays for insured individuals who qualify for their program.

Clients will receive PrEP-AP Benefits as described below:



Minor Clients & Clients with Confidentiality Concerns

Effective immediately, PrEP-AP Network Providers should prescribe generic tenofovir disoproxil fumarate/emtricitabine for clients who are enrolled in PrEP-AP as uninsured because they are 1) minors, or 2) have confidentiality concerns using their own health insurance through a parent, spouse, or domestic partner. If Descovy® is clinically indicated for the client, the clinician can write the prescription as a Dispense as Written (DAW) to allow an override of the generic medication requirement.

Uninsured Clients

PrEP-AP Network Providers should continue to prescribe uninsured PrEP-AP clients brand name Truvada® (or Descovy®). These clients will be required to apply for medication assistance through Gilead's Patient Assistance Program.

Medicare Clients

PrEP-AP will cover the cost of PrEP medication copays for clients with Medicare Part D drug coverage for either generic or brand name PrEP. Medicare clients without Part D drug coverage should be prescribed Truvada® or Descovy®, and are required to apply to Gilead's Patient Assistance Program.

PrEP-AP requests that you share this information with your clinical leadership team and local prescribers. The [PrEP-AP drug formulary](#) has been updated to reflect the addition of generic tenofovir disoproxil fumarate/emtricitabine. Access to the updated formulary is available at the following URL: <https://cdphprep-ap.magellanrx.com/member/documents>.

If you have any questions regarding the PrEP-AP Generic Policy, please contact PrEP-AP Support, at PrEP.Support@cdph.ca.gov.

Thank you,



Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health

Enclosures:

- 1) PrEP-AP Generic PrEP Policy Flowchart